- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03396718
De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head-neck Squamous Cell Carcinomas (DELPHI)
De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head and Neck Squamous Cell Carcinomas: A Phase I Study to Reduce Late Toxicity
In patients with squamous cell carcinoma of the oral cavity, the oropharynx and larynx with local advanced tumors (pathologic stage T3 = pT3) and or lymph node involvement (pN+) postoperative radio - or radiochemotherapy is the standard of care. Postoperative radiochemotherapy is indicated in patients with multiple lymph node metastasis, lymph node metastasis with extracapsular spread and / or residual tumor (R1-Status) after resection. Oropharyngeal cancer caused by HPV (human papillomavirus 16 or 18) is a distinct subgroup with a known sensitivity to radiotherapy (RTx) or radiochemotherapy (RCTx). Additionally a superior outcome after R(C)Tx over HPV negative patients was shown for patients treated with primary or adjuvant RCTx. To date it is unknown if the total dose of the radiotherapy can be safely reduced with the aim to decrease the therapy associated late effects.
Patients with a HPV associated carcinoma that take part in the study will be treated with a reduced radiotherapy dose, chemotherapy will be prescribed based on clinical factors (number of affected lymph node, presence of extracapsular spread or residual tumor). Radiation dose will be reduced in two steps.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Mechthild Krause, Prof.
- Phone Number: +49 351 458 2238
- Email: mechthild.krause@uniklinikum-dresden.de
Study Contact Backup
- Name: Fabian Lohaus, MD
- Phone Number: +49 351 458 2238
- Email: fabian.lohaus@uniklinikum-dresden.de
Study Locations
-
-
-
Berlin, Germany, 10117
- Not yet recruiting
- Prof. Volker Budach
-
Contact:
- Volker Budach, Prof.
- Phone Number: +49 30 450 527 152
-
Principal Investigator:
- Volker Budach, Prof.
-
Heidelberg, Germany
- Recruiting
- Prof. Jürgen Debus
-
Contact:
- Jürgen Debus, Prof.
-
-
Baden-Wuerttemberg
-
Freiburg, Baden-Wuerttemberg, Germany, 79106
- Recruiting
- Prof. Anca-Ligia Grosu
-
Contact:
- Anca-Ligia Grosu, Prof.
- Phone Number: +49 761 270 94610
- Email: anca.grosu@uniklinik-freiburg.de
-
Principal Investigator:
- Ana-Ligia Grosu, Prof.
-
Tübingen, Baden-Wuerttemberg, Germany, 72016
- Recruiting
- Prof. Daniel Zips
-
Contact:
- Daniel Zips, Prof.
- Phone Number: +49 7071/29-8 21 65
- Email: ROInfo@med.uni-tuebingen.de
-
Principal Investigator:
- Daniel Zips, Prof.
-
-
Bavaria
-
München, Bavaria, Germany, 81377
- Recruiting
- Prof. Claus Belka
-
Contact:
- Claus Belka, Prof.
- Phone Number: +49 89 7095 4520
- Email: Claus.Belka@med.uni-muenchen.de
-
Principal Investigator:
- Claus Belka, Prof.
-
München, Bavaria, Germany, 81675
- Recruiting
- Prof. Stephanie Combs
-
Contact:
- Stephanie Combs, Prof.
- Phone Number: +49 89 41 40-45 02
- Email: radonk@lrz.tum.de
-
Principal Investigator:
- Stephanie Combs, Prof.
-
-
Hesse
-
Frankfurt am Main, Hesse, Germany
- Recruiting
- Prof. Claus Rödel
-
Contact:
- Claus Rödel, Prof.
-
-
North Rhine-Westphalia
-
Essen, North Rhine-Westphalia, Germany, 45147
- Recruiting
- Prof. Martin Stuschke
-
Contact:
- Martin Stuschke, Prof.
- Phone Number: +49 201 / 723-23 20
- Email: martin.stuschke@uk-essen.de
-
Principal Investigator:
- Martin Stuschke, Prof.
-
-
Saxony
-
Dresden, Saxony, Germany, 01307
- Recruiting
- Prof. Mechthild Krause
-
Contact:
- Mechthild Krause, Prof.
- Phone Number: +493514582238
- Email: str.studien@uniklinikum-dresden.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Condition after surgical removal of a squamous cell carcinoma of the oropharynx and adequate lymph node dissection
- Indication for adjuvant radiotherapy or radiochemotherapy in the interdisciplinary tumor board
- Good general state (ECOG performance status 0 or 1)
- Adequate compliance to ensure closely follow-up
- Patient's consent and written consent
- Neck dissection of at least the tumor bearing side
Additional Inclusion Criteria Arm intermediate risk (at least one of the criteria must be fulfilled):
- pT3 and R0 and / or
- histologically confirmed involvement of lymph nodes (n = 1-3) and no extracapsular extension of the lymph node metastasis
Additional Inclusion Criteria Arm high risk (at least one of the criteria must be fulfilled):
- residual tumor (R1 status) and / or
- pathologic stage T4 (pT4) status and / or
- more than 3 infected lymph nodes and / or
- extracapsular extension of at least one lymph node metastasis
Exclusion Criteria:
- Patients with a cumulative nicotine abuse > 30 packyears. These patients are not included in the intervention arms, but are always included in the observation arms (regardless of HPV status).
- radiologically presumed or histologically confirmed distant metastasis
- R2 resection or macroscopically visible residual tumor after surgery
- no neck dissection
- interval between last operation and planned irradiation start > 7 weeks
- contraindication against a guideline-appropriate adjuvant radiation or radiochemotherapy according to the clinical risk constellation
- tumor disease in the last five years before the beginning of the study (except basaliomas of the skin, in-situ carcinoma of the cervix uteri or breast, or tumors with similar prognosis which are considered to be very likely to be cured)
- malignant tumor disease in the head and neck region, regardless of interval and prognosis
- Pre-irradiation with risk of dose overlap
- participation in another clinical trial if further experimental therapy is necessary or the treatments/ protocols are mutually exclusive (e.g. altered chemotherapy, additional consolidation chemotherapy). Allowed is the additional participation in observation studies or supportive therapy studies.
- diseases or conditions which do not allow the person concerned to assess the nature and scope and possible consequences of the clinical trial
- pregnant or lactating women
- evidence that the participant is not expected to comply with the study protocol (e.g. lack of cooperation)
- missing written consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Interventional Arm A - HPV(+)
De-escalation Radio(chemo)therapy - Level 1
|
54/ 59,4 Gy
|
Experimental: Interventional Arm B - HPV(+)
De-escalation Radio(chemo)therapy - Level 2
|
48,8/ 55 Gy
|
Active Comparator: Observational Arm A - HPV(-)
Standard Radio(chemo)therapy
|
60/ 66 Gy
|
Active Comparator: Observational Arm B - HPV(+)
Standard Radio(chemo)therapy
|
60/ 66 Gy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
rate of locoregional recurrences
Time Frame: 24 months after end of treatment
|
measured from the last day of treatment
|
24 months after end of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall survival
Time Frame: 60 months and 5 years after end of treatment
|
measured from the last day of treatment
|
60 months and 5 years after end of treatment
|
acute toxicity
Time Frame: 3 months after end of treatment
|
The occurrence of acute side effects (up to 90 days after start of treatment) will be recorded and documented based on CTCAE 4.0.
|
3 months after end of treatment
|
late toxicity
Time Frame: 24 months after end of treatment
|
The occurrence of late side effects will be recorded and documented based on CTCAE 4.0 after every follow-up visit.
|
24 months after end of treatment
|
quality of life of cancer patients
Time Frame: 24 months after end of treatment
|
The assessment of quality of life (QoL) is carried out using the EORTC quality of life questionnaire (QLQ) C30.
Quality of life will be documented immediately before the start of therapy, after completion of postoperative radiotherapy and at every follow-up visit.
QOL will be measured as change from baseline over time.
|
24 months after end of treatment
|
quality of life - disease specific
Time Frame: 24 months after end of treatment
|
The assessment of quality of life (QOL) is carried out using the EORTC quality of life questionnaire (QLQ) disease-specific module for head and neck cancer H&N35.
Quality of life will be documented immediately before the start of therapy, after completion of postoperative radiotherapy and at every follow-up visit.
QOL will be measured as change from baseline over time.
|
24 months after end of treatment
|
rate of locoregional recurrences
Time Frame: 5 years after end of treatment
|
measured from the last day of treatment
|
5 years after end of treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Mechthild Krause, Prof., University of Technology, University Hospital Carl Gustav Carus, Department of Radiation Therapy and Radiation Oncology, German Consortium for Translational Cancer Research (DKTK)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STR-DELPHI-2016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head-and-neck Squamous Cell Carcinoma
-
Washington University School of MedicineMerck Sharp & Dohme LLCActive, not recruitingHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Carcinoma, Squamous Cell of Head and Neck | Neoplasms, Head and Neck | Squamous Cell Carcinoma, Head and NeckUnited States
-
Xiang LuRecruitingHead and Neck Squamous Cell Carcinomas | Resectable Head and Neck Squamous-cell CarcinomaChina
-
Chase Heaton, MDIncyte Corporation; OncoSec Medical IncorporatedTerminatedRecurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Unresectable Head and Neck Squamous Cell CarcinomaUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingRecurrent Head and Neck Squamous Cell Carcinoma | Advanced Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma | Locally Advanced Head and Neck Squamous Cell Carcinoma | Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage IV Cutaneous...United States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingHead and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell CarcinomaUnited States
-
Washington University School of MedicineActive, not recruitingSquamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma, Head and NeckUnited States
-
Yonsei UniversityCompletedHead Neck Cancer Squamous Cell Recurrent | Head Neck Cancer Squamous Cell MetastaticKorea, Republic of
-
National Taiwan University HospitalUnknownHead-and-Neck Squamous Cell CarcinomaTaiwan
-
Eben RosenthalNational Cancer Institute (NCI)CompletedHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN)United States
-
Shanghai Ninth People's Hospital Affiliated to...RecruitingRecurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell CarcinomaChina
Clinical Trials on De-escalation radio(chemo)therapy - Level 1
-
Maria Sklodowska-Curie National Research Institute...Polish Society of Surgical OncologyRecruitingRectal Cancer | Rectal NeoplasmsPoland
-
Lawson Health Research InstituteOntario Institute for Cancer ResearchActive, not recruiting
-
Rigshospitalet, DenmarkActive, not recruitingQuality of Life | Pain | Oropharynx Cancer | Human Papilloma Virus | Swallowing Disorder | Saliva AlteredDenmark
-
MVZ Leopoldina GmbHCompleted
-
Seoul National University HospitalLudwig-Maximilians - University of Munich; ST. Antonius hospital NieuwegeinRecruitingCoronary Artery Disease | Acute Coronary SyndromeKorea, Republic of
-
Northern State Medical UniversityCompletedARDS, Human | Sepsis, SevereRussian Federation
-
China National Center for Cardiovascular DiseasesRecruitingMyocardial Infarction | Myocardial Ischemia | Coronary Artery Disease | Bleeding | Angina Pectoris | Dual Antiplatelet Therapy | Coronary Artery Bypass GraftingChina
-
Mayo ClinicCompleted
-
University Rovira i VirgiliUniversity of Valladolid; Sanidad de Castilla y LeónUnknownBurns | Nurse's Role | Thermal Injury
-
Rodrigo Della Méa PlentzFederal University of Health Science of Porto AlegreUnknown